Please login to the form below

Not currently logged in
Email:
Password:

Roche’s Torsten Hoffmann to join Zealand Pharma

Joins the Danish biotech as chief scientific officer

Zealand Pharma Torsten Hoffmann Dr Torsten Hoffmann has left his senior role at pharma company Roche to join the Danish biotech Zealand Pharma as chief scientific officer.

Dr Hoffmann (pictured) was head of head of discovery chemistry, pharma research, at Roche – a role he'd held since 2005.

He initially joined the company in 1997 as a laboratory head before working his way up the ranks in early-stage science, and was responsible for the identification of more than 25 drug candidates that entered clinical development.

In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity.

Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it as Lyxumia for the treatment of type 2 diabetes.

"These are exciting times for the company following the launch of its first discovered medicine,” commented Dr Hoffmann.

As chief scientific officer, Dr Hoffmann will be expected to further drive innovation and strengthen Zealn's research efforts, which includes collaborations with Boehringer Ingelheim and Lilly.

“Torsten is known for being a strong and collaborative leader and his impressive and impactful scientific record plus wealth of sector experience and innovative ideas will be extremely valuable to our company,” said Zealand's CEO David Solomon.

“I am confident that under his leadership, we can drive Zealand's R&D activities further towards tomorrow's breakthrough peptide therapeutics.”

4th September 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....